LYTIR

Insider · SEC Form 4 · President/CEO and Board Chair

Azamian Bobak R.

In the 12 months to Nov 8, 2026, on the open market: sold $2.3M of TARS. Filed a median of 2 business days after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

Insider purchases and sales, by month (last 12 months)Insider purchases: $0 in total; Insider sales: $2.3M in total.Jun: Insider sales $615KSep: Insider sales $1.7MDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $0Insider sales below: $2.3M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.
  1. TARSSold: Tarsus Pharmaceuticals, Inc. Sep 4, 2026 10,000 shares filed Sep 9, 2026 2 transactions 10b5-1 plan filing $906K
  2. TARSSold: Tarsus Pharmaceuticals, Inc. Sep 2, 2026 10,000 shares filed Sep 3, 2026 837,991 shares held indirectly after, as filed 10b5-1 plan filing $801K
  3. TARSSold: Tarsus Pharmaceuticals, Inc. Jun 17, 2026 10,000 shares filed Jun 22, 2026 2 transactions 10b5-1 plan filing $615K

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.